RESPECT-EPA: Randomised trial for Evaluation in Secondary Prevention Efficacy of  Combination Therapy – Statin and Eicosapentaenoic Acid (RESPECT-EPA) (UMIN000012069, completed)

In patients with coronary artery disease (CAD) and relatively low baseline EPA/arachidonic acid (AA) ratio, on statin treatment, icosapent ethyl treatment resulted in a numerically lower risk of cardiovascular events that did not reach statistical significance.